Molecular remodeling in comorbidities associated with heart failure: a current update
Sandeep Appunni1, Muni Rubens2,3,4, Venkataraghavan Ramamoorthy5
1Government Medical College, Kozhikode, Kerala, India.
Molecular Biology Reports
|October 26, 2024
Summary
This review details molecular changes in heart failure comorbidities like obesity and diabetes. Understanding these pathways can lead to new, personalized treatments for heart failure patients.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Genomics and Proteomics
Background:
- Heart failure frequently co-occurs with comorbidities such as obesity, diabetes, hypertension, and coronary artery disease.
- Established associations between comorbidities and heart failure are now being explored at a deeper molecular level.
- Genomics and proteomics advances provide new insights into the complex interplay between heart failure and its common comorbidities.
Purpose of the Study:
- To review the molecular alterations in common comorbidities associated with heart failure.
- To elucidate how understanding these molecular pathways can inform the development of novel heart failure therapeutics.
- To highlight the potential for personalized medicine strategies in treating heart failure with comorbidities.
Main Methods:
- A narrative review of electronic databases including PubMed, Ovid, EMBASE, Google Scholar, CINAHL, and PhysioNet.
- Articles were searched without time restriction to capture recent advances.
- Focus on molecular mechanisms and pathways linking comorbidities to heart failure.
Main Results:
- Detailed molecular alterations in obesity, diabetes mellitus, systemic hypertension, pulmonary hypertension, coronary artery disease, hypercholesteremia, chronic kidney disease, and atrial fibrillation were reviewed.
- Recent studies offer in-depth exploration of molecular pathways, revealing how novel heart failure drugs interact with comorbidity-associated pathways.
- The altered molecular milieu in heart failure and comorbidities presents targets for new drug development.
Conclusions:
- Understanding the molecular basis of heart failure comorbidities is crucial for developing targeted and novel medications.
- Personalized therapeutic approaches incorporating individual molecular variations can improve treatment outcomes.
- This knowledge is essential for advancing precision medicine strategies in cardiovascular care.
Related Concept Videos
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:29Heart Failure II: Pathophysiology
1
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
01:27Heart Failure I: Introduction
1
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1
01:30Heart Failure V: Medical Management
1
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
1
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...